Form 4 for BCAX Bicara Therapeutics Inc.
Accepted 2026-03-05 00:00:00 ET · period of report 2026-03-03 · accession 0001628280-26-015419 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-03-05 | 2026-03-03+ | BCAX | Raben David | Chief Medical Off | S - Sale+OE | $18.52 | -16.5K | 55.3K | -23% | -$305.6K |
| DM | 2026-03-05 | 2026-03-03+ | BCAX | Raben David | Chief Medical Off | M - OptEx | $3.79 | +16.5K | 55.5K | +42% | +$62.5K |
| DM | 2026-03-05 | 2026-03-03+ | BCAX | Raben David | Chief Medical Off | M - OptEx | $0.00 | -16.5K | 69.2K | -19% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-03 | S | D | 200 | $18.45 | 55,286 | D | — | — | |
| 2 | Common | Common Stock | 2026-03-04 | M | A | 16,300 | $3.79 | 71,586 | D | — | — | |
| 3 | Common | Common Stock | 2026-03-03 | M | A | 200 | $3.79 | 55,486 | D | — | — | |
| 4 | Common | Common Stock | 2026-03-04 | S | D | 16,300 | $18.52 | 55,286 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.45 to $18.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
| 5 | Derivative | Stock Option (Right to Buy) | 2026-03-04 | M | D | 16,300 | $0.00 | 52,913 | D | $3.79 · — to 2023-08-08 | 16,300 Common Stock | (F3) The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. |
| 6 | Derivative | Stock Option (Right to Buy) | 2026-03-03 | M | D | 200 | $0.00 | 69,213 | D | $3.79 · — to 2023-08-08 | 200 Common Stock | (F3) The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date. |